PMID- 31588250
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1849-4544 (Electronic)
IS  - 1849-4544 (Linking)
VI  - 8
DP  - 2019 Jan-Dec
TI  - Plasma vitronectin is reduced in patients with myasthenia gravis: Diagnostic and 
      pathophysiological potential.
PG  - 1849454419875912
LID - 10.1177/1849454419875912 [doi]
LID - 1849454419875912
AB  - Myasthenia gravis (MG) is an autoimmune disease leading to varying degrees of 
      skeletal muscle weakness. It is caused by specific antibodies directed against 
      definite components in the postsynaptic membrane at the neuromuscular junction 
      (NMJ), such as the acetylcholine receptor (AChR) and the muscle-specific kinase 
      (MUSK) receptor. In clinical practice, MG patients may be classified into three 
      main subgroups based on the occurrence of serum autoantibodies directed against 
      AChR or MUSK receptor or antibody-negative. As the MG subgroups differ in terms 
      of clinical characteristics, disease pathogenesis, prognosis, and response to 
      therapies, they could benefit from targeted treatment as well as the detection of 
      other possible disease biomarkers. We performed proteomics on plasma fractions 
      enriched in low-abundance proteins to identify potential biomarkers according to 
      different autoimmune responses. By this approach, we evidenced a significant 
      reduction of vitronectin in MG patients compared to healthy controls, 
      irrespective of the autoantibodies NMJ target. The obtained results were 
      validated by mono- and two-dimensional Western blotting analysis. Vitronectin is 
      a multifunctional glycoprotein involved in the regulation of several 
      pathophysiological processes, including complement-dependent immune response, 
      coagulation, fibrinolysis, pericellular proteolysis, cell attachment, and 
      spreading. The pathophysiological significance of the reduction of plasma 
      vitronectin in MG patients has yet to be fully elucidated. It could be related 
      either to a possible deposition of vitronectin at NMJ to counteract the 
      complement-mediated muscle damage at this level or to a parallel variation of 
      this glycoprotein in the muscle extracellular matrix with secondary induced 
      alteration in clustering of AChRs at NMJ, as it occurs with variation in 
      concentrations of agrin, another extracellular matrix component. The clinical 
      value of measuring plasma vitronectin has yet to be defined. According to present 
      findings, significantly lower plasma values of this glycoprotein might be 
      indicative of an impaired complement-dependent immune response.
CI  - (c) The Author(s) 2019.
FAU - Lepedda, Antonio Junior
AU  - Lepedda AJ
AUID- ORCID: 0000-0002-8356-894X
AD  - Department of Biomedical Sciences, University of Sassari, Viale San Pietro, 
      Sassari, Italy.
FAU - Deiana, Giovanni Andrea
AU  - Deiana GA
AD  - Department of Medical, Surgical and Experimental Sciences, University of Sassari, 
      Viale San Pietro, Sassari, Italy.
FAU - Lobina, Omar
AU  - Lobina O
AD  - Department of Biomedical Sciences, University of Sassari, Viale San Pietro, 
      Sassari, Italy.
FAU - Nieddu, Gabriele
AU  - Nieddu G
AD  - Department of Biomedical Sciences, University of Sassari, Viale San Pietro, 
      Sassari, Italy.
FAU - Baldinu, Paola
AU  - Baldinu P
AD  - Department of Biomedical Sciences, University of Sassari, Viale San Pietro, 
      Sassari, Italy.
FAU - De Muro, Pierina
AU  - De Muro P
AD  - Department of Biomedical Sciences, University of Sassari, Viale San Pietro, 
      Sassari, Italy.
FAU - Andreetta, Francesca
AU  - Andreetta F
AD  - Diagnostic Laboratory of Neuroimmunolgy, U.O. Neurologia IV, I.R.C.C.S. 
      Fondazione Istituto Neurologico "C. Besta", Milano, Italy.
FAU - Sechi, Elia
AU  - Sechi E
AD  - Department of Medical, Surgical and Experimental Sciences, University of Sassari, 
      Viale San Pietro, Sassari, Italy.
FAU - Arru, Giannina
AU  - Arru G
AD  - Department of Medical, Surgical and Experimental Sciences, University of Sassari, 
      Viale San Pietro, Sassari, Italy.
FAU - Corda, Davide Giacomo
AU  - Corda DG
AD  - Department of Medical, Surgical and Experimental Sciences, University of Sassari, 
      Viale San Pietro, Sassari, Italy.
FAU - Sechi, Gian Pietro
AU  - Sechi GP
AD  - Department of Medical, Surgical and Experimental Sciences, University of Sassari, 
      Viale San Pietro, Sassari, Italy.
FAU - Formato, Marilena
AU  - Formato M
AD  - Department of Biomedical Sciences, University of Sassari, Viale San Pietro, 
      Sassari, Italy.
LA  - eng
PT  - Journal Article
DEP - 20190911
PL  - United States
TA  - J Circ Biomark
JT  - Journal of circulating biomarkers
JID - 101703517
PMC - PMC6740073
OTO - NOTNLM
OT  - Myasthenia gravis
OT  - autoimmunity
OT  - biomarkers
OT  - proteomics
OT  - vitronectin
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2019/10/08 06:00
MHDA- 2019/10/08 06:01
PMCR- 2019/09/12
CRDT- 2019/10/08 06:00
PHST- 2019/02/19 00:00 [received]
PHST- 2019/08/18 00:00 [accepted]
PHST- 2019/10/08 06:00 [entrez]
PHST- 2019/10/08 06:00 [pubmed]
PHST- 2019/10/08 06:01 [medline]
PHST- 2019/09/12 00:00 [pmc-release]
AID - 10.1177_1849454419875912 [pii]
AID - 10.1177/1849454419875912 [doi]
PST - epublish
SO  - J Circ Biomark. 2019 Sep 11;8:1849454419875912. doi: 10.1177/1849454419875912. 
      eCollection 2019 Jan-Dec.